Benzinga·Jun 26, 2026
What's Going On With Capricor Therapeutics Stock On Friday?Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.
Capricor Therapeutics, Inc.(CAPR)Earnings, Financials & Key Ratios
CAPR•NASDAQ
$22.43
Price updated Jul 6, 2026
AboutCapricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.Show more
- Revenue$0-100.0%
- EBITDA-$108M-162.9%
- Net Income-$105M-159.6%
- EPS (Diluted)-2.26-96.5%
- ROE-46.56%+3.3%
CAPR Price & Volume
Capricor Therapeutics, Inc. (CAPR) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Significant Operational Burn
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Contracting
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Binary Clinical Trial Outcome
Key Thesis Takeaways
- Capricor Therapeutics is currently in a high-stakes transition to a pre-revenue clinical-stage firm, with its valuation tethered to the BLA submission for CAP-1002.
- While the company has bolstered its liquidity to $105.4 million as of 2026Q1, the path to commercialization remains fraught with binary clinical risks and the necessity of scaling complex manufacturing.
- Investors should monitor the firm's ability to manage its $27.4 million quarterly R&D burn rate against the backdrop of an accumulated deficit that has reached $338.8 million.
Verdict Logic
while the firm maintains a liquidity buffer of $105.4 million, the lack of commercial revenue and the $40.0 million quarterly free cash flow burn necessitate extreme caution regarding future dilution risks.
CAPR Growth Metrics
Capricor Therapeutics, Inc. (CAPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-108.11%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-63.38%
Return on Capital
10 Years-85.9%
5 Years-67.49%
3 Years-61.13%
Last Year-46.06%
CAPR Recent Earnings
Capricor Therapeutics, Inc. (CAPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (57%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.59-7.3%
$0.55
Rev
—
$40M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.62-21.6%
$0.51
Rev
—
$525,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.54+0.0%
$0.54
Rev
—
$600,000
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.57-18.8%
$0.48
Rev
—
$480,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.59vs $0.55-7.3% | —vs $40M |
| Q2 2026 | Mar 12, 2026 | $0.62vs $0.51-21.6% | —vs $525,000 |
| Q4 2025 | Nov 10, 2025 | $0.54vs $0.54+0.0% | —vs $600,000 |
| Q3 2025 | Aug 11, 2025 | $0.57vs $0.48-18.8% | —vs $480,000 |
Based on last 12 quarters of dataView full earnings history →
Latest CAPR News
Recent stock market news and headlines for Capricor Therapeutics, Inc. (CAPR)
GlobeNewsWire·Jun 26, 2026
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–
GlobeNewsWire·Jun 26, 2026
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual ConferenceSAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company's lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company's HOPE-3 Phase 3 trial.
Newsfile Corp·Jun 19, 2026
Caprock Announces Closing of Private PlacementToronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement offering of 6,000,000 flow-through shares (the "FT Shares") at a price of $0.10 per FT Share for aggregate gross proceeds of $600,000 (the "Offering"). The Offering was initially announced in the Company's press release dated June 12, 2026.
Newsfile Corp·Jun 17, 2026
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Issuer") through the facilities of the Canadian Securities Exchange for total consideration of $19,136.00 CAD (the "Acquisition"). Immediately prior to the Acquisition, the Acquiror held 20,602,166 common shares and 4,633,333 common share purchase warrants of the Issuer, representing approximately 19.35% of Caprock's issued and outstanding common shares assuming exercise of the common share purchase warrants held by the Acquiror.
Peers Comparison
Key metrics vs top competitors for Capricor Therapeutics, Inc. (CAPR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.43 | $1.03B | -9.92 | -100% | — | -46.56% | — | |
| $19.18 | $2.02B | -2.69 | 15.58% | 2.98% | 4.89% | — | |
| $61.89 | $5.97B | -9.57 | -89.97% | -13856.54% | -30.88% | — | |
| $55.53 | $14.11B | 19.97 | 6.98% | 35.08% | 40.21% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — |
Compare CAPR vs Peers
Capricor Therapeutics, Inc. (CAPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CAPR SEC Filings & Documents
Capricor Therapeutics, Inc. (CAPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when CAPR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CAPR Frequently Asked Questions
Capricor Therapeutics, Inc. (CAPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Capricor Therapeutics, Inc. growing?
Capricor Therapeutics, Inc. (CAPR) saw revenue decline by 100.0% over the past year.
Is CAPR profitable?
Capricor Therapeutics, Inc. (CAPR) reported a net loss of $114.6M for fiscal year 2025.
Dividend & Returns
What is CAPR's return on equity?
Capricor Therapeutics, Inc. (CAPR) has a return on equity (ROE) of -46.6%. Negative ROE indicates the company is unprofitable.
What is Capricor Therapeutics, Inc.'s free cash flow?
Capricor Therapeutics, Inc. (CAPR) had negative free cash flow of $114.0M in fiscal year 2025, likely due to heavy capital investments.